Published in PLoS One on April 25, 2014
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Natural history of untreated breast cancer (1805-1933). Comparison of untreated and treated cases according to histological grade of malignancy. Br Med J (1962) 3.14
Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol (2005) 3.01
"Westernizing" women's risks? Breast cancer in lower-income countries. N Engl J Med (2008) 2.85
Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ (2005) 2.75
Use of statistics to assess the global burden of breast cancer. Breast J (2006) 2.56
Kerala, India: a regional community-based palliative care model. J Pain Symptom Manage (2007) 2.39
Health insurance in Mexico: achieving universal coverage through structural reform. Health Aff (Millwood) (2005) 2.22
Does aggressive local therapy improve survival in metastatic breast cancer? Surgery (2002) 2.13
Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst (2000) 1.98
Breast cancer care in developing countries. World J Surg (2009) 1.91
Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J (2006) 1.85
A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol (2005) 1.83
Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol (2011) 1.77
Reducing by half the percentage of late-stage presentation for breast and cervix cancer over 4 years: a pilot study of clinical downstaging in Sarawak, Malaysia. Ann Oncol (2007) 1.58
Outcome of screening by clinical examination of the breast in a trial in the Philippines. Int J Cancer (2006) 1.54
The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer (1998) 1.54
Symptom clustering in advanced cancer. Support Care Cancer (2006) 1.49
Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J (2006) 1.40
Breast cancer in limited-resource countries: health care systems and public policy. Breast J (2006) 1.35
Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis. BMJ (2012) 1.31
Breast cancer in Mexico: a pressing priority. Reprod Health Matters (2008) 1.20
Breast cancer in Latin America and the Caribbean. Rev Panam Salud Publica (2002) 1.18
Breast cancer mortality in Mexico: an age-period-cohort analysis. Salud Publica Mex (2009) 1.08
Costs, effects and cost-effectiveness of breast cancer control in Ghana. Trop Med Int Health (2012) 1.05
[Public policies for the detection of breast cancer in Mexico]. Salud Publica Mex (2009) 1.03
[The health care costs of breast cancer: the case of the Mexican Social Security Institute]. Salud Publica Mex (2009) 1.02
Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol (2011) 0.95
Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol (2002) 0.93
[Regional differences in breast and cervical cancer mortality in Mexico between 1979-2006]. Salud Publica Mex (2009) 0.93
Introduction of breast cancer screening in Chernihiv Oblast in the Ukraine: report of a PATH Breast Cancer Assistance Program experience. Breast J (2003) 0.88
What should the detection rates of cancers be in breast screening programmes? Br J Cancer (2005) 0.88
Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Value Health (2011) 0.88
[Government actions for the early detection of breast cancer in Latin America. Future challenges]. Salud Publica Mex (2011) 0.82
[Prognostic factors related to breast cancer survival]. Salud Publica Mex (2008) 0.78
[Epidemiology of cancer of the breast in Mexico. Consequences of demography transition]. Salud Publica Mex (1997) 0.76